At Cedar, we believe in the vision that population health and welfare are enhanced by the development and diffusion of innovative healthcare technologies.
To promote this vision, we conduct evidence-based research on the comparative value of health care technologies. For the past two decades, our research has paved the way for breakthrough drugs, devices, and diagnostics to play effective roles in various health care settings.
Our leadership has a unique blend of experience that combines medical and academic training with a pragmatic understanding of challenges of research, and best practices for innovation adoption. Success hinges on a collaborative model, which we find includes payers, providers, key opinion leaders, and medical policy organizations.
A team of researchers at the Mayo Clinic and at Cedar Associates assessed the burden of treatment-resistant depression—depression that fails to respond to one or more rounds of treatment with drug therapy. They compiled published data about the clinical, societal, and economic outcomes of treatment-resistant depression. The annual US cost of treatment-resistant depression is $29-$48 billion, contributing approximately one-fourth to the total costs of major depression ($106-$118 billion).